Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
Coats CJ, Masri A, Barriales-Villa R, Abraham TP, Brinkley DM, Claggett BL, Hagege A, Hegde SM, Ho CY, Kulac IJ, Lee MMY, Maron MS, Olivotto I, Owens AT, Solomon SD, Tfelt-Hansen J, Watkins HC, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Januzzi JL; SEQUOIA-HCM Investigators.
Coats CJ, et al. Among authors: kulac ij.
Eur Heart J. 2024 Sep 1:ehae590. doi: 10.1093/eurheartj/ehae590. Online ahead of print.
Eur Heart J. 2024.
PMID: 39217447